Please ensure Javascript is enabled for purposes of website accessibility

Nephron CEO elected to National Association of Manufacturers board

Staff Report //March 2, 2021//

Nephron CEO elected to National Association of Manufacturers board

Staff Report //March 2, 2021//

Listen to this article

Nephron Pharmaceuticals Corp. owner and CEO Lou Kennedy has been elected to the National Association of Manufacturers board of directors.

NAM is the largest manufacturing association in the U.S., representing companies in all 50 states.

“I could not be more excited and honored to join the board,” Kennedy said in a news release. “Our team has been fortunate to work with NAM over the last few years on critical issues, from COVID-19 to workforce development, and we are always impressed by the results NAM delivers for its members, as well as for employers and employees across the nation.”

Board members play a key role in the NAM’s “Creators Wanted” campaign, an initiative to aimed at encouraging people to pursue careers in modern manufacturing. 

“Lou Kennedy is a recognized leader in our industry, and the NAM will be stronger thanks to her service on our board of directors,” Jay Timmons, NAM president and CEO, said in the release. “Manufacturers are the driving force behind our economic recovery and our fight to defeat COVID-19. We are working with lawmakers to ensure they deliver the relief America needs and the long-term policy work on issues like infrastructure investment, immigration reform, trade expansion and workforce development.”

Based in West Columbia, Nephron develops and produces generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America and recently opened a CLIA-certified diagnostics lab.

Nephron, which is conducting COVID-19 testing and administering vaccines, is completing a $215.8 million expansion at its Saxe-Gotha Industrial park campus which will include the establishment of a vaccine production facility.

o